August 2, 2016
BioXcel's BDI-Lab is uniquely able to generate optimal therapeutic value by using big data analytics to determine products with higher likelihood of commercial and clinical success. With several clinical partnerships in diverse applications, it is expected that this partnership will drive innovations in the chronic pain therapeutic industry. For more information on this partnership, visit http://bit.ly/29EdTgM.
Randall Stevens, Chief Medical Officer at Centrexion Therapeutics, will be discussing this partnership and his company's research at Arrowhead's 10th Annual Pain & Migraine Therapeutics Summit, held October 19-20, 2016 in Chicago, IL. For more information on the conference, visit http://paintherapeuticsummit.com.
Regarding the potential for this partnership, Centrexion Therapeutics is optimistic that this collaboration will create a portfolio of chronic pain therapeutics. Chief Business Officer Kerrie Brady states, "This partnership allows us to combine our distinctive translational medicine approach with BioXcel's world-class big data platform and discovery engine to develop new non-opioid therapies to treat chronic pain."
The 10th Annual Pain & Migraine Therapeutics Summit is the US's premier pain conference covering the field of pain research and therapeutics. With various stakeholders in pharmaceutical, biotech, device and medical communities attending, this conference will provide multi-faceted perspectives on the latest pain research. For more information, please download a brochure at: www.paintherapeuticsummit.com/brochure.
For more information, please contact:
John Waslif: Managing Director
866-945-0263 ext 700